Showing 1621-1630 of 10578 results for "".
- Risk Stratification Testing for Melanomahttps://practicaldermatology.com/series/c-suite-chats/risk-stratification-testing-for-melanoma/32838/Derek Maetzold, president and CEO of Castle Biosciences, discusses the importance of personalized management and treatment approaches for patients diagnosed with melanoma, and how gene expression profile testing can help.
Choosing and Switching Biologics
https://practicaldermatology.com/topics/psoriasis/choosing-and-switching-biologics/19182/Managing Moderate-to-Severe Psoriasis
https://practicaldermatology.com/topics/psoriasis/managing-moderate-to-severe-psoriasis/19184/Comparing Sunscreen for Skin of Color: Print-Ready Charts for Download
https://practicaldermatology.com/topics/skin-cancer-photoprotection/comparing-sunscreen-for-skin-of-color-print-ready-charts/56515/Click the image to download the print-ready PDFsWound Closure After Mohs Surgery
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/wound-closure-after-mohs-surgery/54648/Anna Bar, MD, discusses key takeaways from the “Wound Closures” workshop at Maui Derm Hawaii 2026.2015 Cosmetic Surgery Forum: Jeanine Downie, MD
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/2015-cosmetic-surgery-forum-jeanine-downie-md/18264/Seborrheic Keratoses: Improve Your Diagnostic Skill
https://practicaldermatology.com/topics/general-topics/PD0305FeaKeratoses-pdf/22235/Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyGLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muMelanoma and the Predictive Value of Nevi: Unexpected Findings?
https://practicaldermatology.com/topics/practice-management/melanoma-and-the-predictive-value-of-nevi-unexpected-findings/20936/A new analysis shows that the association between nevi and melanoma is complex.